Literature DB >> 15557724

Tilt training for recurrent neurocardiogenic syncope: effectiveness, patient compliance, and scheduling the frequency of training sessions.

Ozan Kinay1, Mehmet Yazici, Cem Nazli, Gurkan Acar, Omer Gedikli, Ahmet Altinbas, Halil Kahraman, Abdullah Dogan, Mehmet Ozaydin, Nurullah Tuzun, Oktay Ergene.   

Abstract

Unsatisfactory results obtained with medical therapy and dual-chamber pacing for prevention of recurrent neurocardiogenic syncope necessitated the development of new treatment modalities. Tilt-training, a novel treatment for recurrent neurocardiogenic syncope based on exercise sessions with prolonged upright posture (either on a tilt-table or standing on foot against a wall), was shown to be effective in preventing the recurrence of neurocardiogenic syncope. The purpose of this study was to demonstrate the long-term beneficial effects of a transient tilt training program lasting 2 months. Thirty-two patients with recurrent neurocardiogenic syncope (mean number of syncope episodes in the last 6 months was 3.4 +/- 2.3) constituted the study group. All of the patients were tilt test positive. The patients were taught a tilt training program with 2 phases (in-hospital training with repeated tilt procedures until 3 consecutive negative results were obtained and home exercises with standing against a wall) and home exercises lasted a maximum of 2 months. After this training program, the patients received no treatment and were followed for the recurrence of syncope. At the end of the follow-up period (376 +/- 45 days), 81% of the patients were free of recurrent syncope. This study revealed that similar successful results can also be obtained with a transient tilt training program as a first line treatment strategy. Less interference with the daily activities of the patients is the major advantage of this strategy. The ease of performance and high effectiveness rate will most likely result in more frequent utilization of this treatment modality.

Entities:  

Mesh:

Year:  2004        PMID: 15557724     DOI: 10.1536/jhj.45.833

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  7 in total

Review 1.  Current concepts in the evaluation and management of syncope.

Authors:  Vikas Kuriachan; Robert S Sheldon
Journal:  Curr Cardiol Rep       Date:  2008-09       Impact factor: 2.931

2.  Guidelines for the diagnosis and management of syncope (version 2009).

Authors:  Angel Moya; Richard Sutton; Fabrizio Ammirati; Jean-Jacques Blanc; Michele Brignole; Johannes B Dahm; Jean-Claude Deharo; Jacek Gajek; Knut Gjesdal; Andrew Krahn; Martial Massin; Mauro Pepi; Thomas Pezawas; Ricardo Ruiz Granell; Francois Sarasin; Andrea Ungar; J Gert van Dijk; Edmond P Walma; Wouter Wieling
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

3.  Human and monkey prolactin and growth hormone: separation of polymorphic forms by isoelectric focusing.

Authors:  B C Hummel; G M Brown; P Hwang; H G Friesen
Journal:  Endocrinology       Date:  1975-10       Impact factor: 4.736

4.  Advances in syncope: with emphasis on reflex syncope.

Authors:  John D Fisher
Journal:  J Interv Card Electrophysiol       Date:  2011-06-07       Impact factor: 1.900

5.  Physical training as non-pharmacological treatment of neurocardiogenic syncope.

Authors:  Vanessa Cristina Miranda Takahagi; Daniela Caetano Costa; Júlio César Crescêncio; Lourenço Gallo Junior
Journal:  Arq Bras Cardiol       Date:  2014-03       Impact factor: 2.000

6.  Vestibular Activation Habituates the Vasovagal Response in the Rat.

Authors:  Bernard Cohen; Giorgio P Martinelli; Yongqing Xiang; Theodore Raphan; Sergei B Yakushin
Journal:  Front Neurol       Date:  2017-03-15       Impact factor: 4.003

7.  Utilization of Echocardiogram, Carotid Ultrasound, and Cranial Imaging in the Inpatient Investigation of Syncope: Its Impact on the Diagnosis and the Patient's Length of Hospitalization.

Authors:  Glenmore Lasam; Jaimin Dudhia; Sharen Anghel; Jeffrey Brensilver
Journal:  Cardiol Res       Date:  2018-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.